Loyola University Chicago

Loyola eCommons
Biology: Faculty Publications and Other Works

Faculty Publications and Other Works by
Department

5-11-2018

Caspase-3 suppresses diethylnitrosamine-induced hepatocyte
death, compensatory proliferation and hepatocarcinogenesis
through inhibiting p38 activation
Na Shang
Loyola University Chicago Stritch School of Medicine

Thomas Bank
Loyola University Chicago Stritch School of Medicine

Xianzhong Ding
Loyola University Chicago Stritch School of Medicine

Peter W. Breslin
Loyola University Chicago, pbreslin@luc.edu

Jun Li
University
Notre
Dame works at: https://ecommons.luc.edu/biology_facpubs
Follow thisofand
additional
Part of the Biology Commons

See next page for additional authors

Recommended Citation
Shang, Na; Bank, Thomas; Ding, Xianzhong; Breslin, Peter W.; Li, Jun; Shi, Baomin; and Qiu, Wei. Caspase-3
suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and
hepatocarcinogenesis through inhibiting p38 activation. Cell Death & Disease, 9, : , 2018. Retrieved from
Loyola eCommons, Biology: Faculty Publications and Other Works, http://dx.doi.org/10.1038/
s41419-018-0617-7

This Article is brought to you for free and open access by the Faculty Publications and Other Works by Department
at Loyola eCommons. It has been accepted for inclusion in Biology: Faculty Publications and Other Works by an
authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Shang et al., 2018.

Authors
Na Shang, Thomas Bank, Xianzhong Ding, Peter W. Breslin, Jun Li, Baomin Shi, and Wei Qiu

This article is available at Loyola eCommons: https://ecommons.luc.edu/biology_facpubs/128

Shang et al. Cell Death and Disease
DOI 10.1038/s41419-018-0617-7

ARTICLE

Cell Death & Disease

Open Access

Caspase-3 suppresses diethylnitrosamineinduced hepatocyte death, compensatory
proliferation and hepatocarcinogenesis
through inhibiting p38 activation

1234567890():,;
1234567890():,;

Na Shang1, Thomas Bank1, Xianzhong Ding2, Peter Breslin1,3, Jun Li4, Baomin Shi5 and Wei Qiu1,5

Abstract
It is critical to understand the molecular mechanisms of hepatocarcinogenesis in order to prevent or treat
hepatocellular carcinoma (HCC). The development of HCC is commonly associated with hepatocyte death and
compensatory proliferation. However, the role of Caspase-3, a key apoptotic executor, in hepatocarcinogenesis is
unknown. In this study, we used Caspase-3-deﬁcient mice to examine the role of Caspase-3 in hepatocarcinogenesis in
a chemical (diethylnitrosamine, DEN)-induced HCC model. We found that Caspase-3 deﬁciency signiﬁcantly increased
DEN-induced HCC. Unexpectedly, Caspase-3 deﬁciency increased apoptosis induced by DEN and the subsequent
compensatory proliferation. Intriguingly, we discovered that Caspase-3 deﬁciency increased the activation of p38 with
and without DEN treatment. Moreover, we demonstrated that TNFα and IL1α stimulated increased activation of p38 in
Caspase-3 KO hepatocytes compared with wild-type hepatocytes. Finally, we found that inhibition of p38 by SB202190
abrogated enhanced hepatocyte death, compensatory proliferation and HCC induced by DEN in Caspase-3-deﬁcient
mice. Overall, our data suggest that Caspase-3 inhibits chemical-induced hepatocarcinogenesis by suppressing p38
activation and hepatocyte death.

Introduction
Hepatocellular carcinoma (HCC) is the second leading
cause of cancer deaths worldwide1. The overall survival of
patients with HCC is <12%, and most patients with HCC
have limited treatment options2. Currently, the most
effective targeted therapeutic agent for advanced HCC,
sorafenib, only increases survival in patients with
advanced HCC from 7.9 months to 10.7 months3. There is
an urgent need to develop more effective therapeutic
strategies and agents to treat HCC. To achieve this goal,
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the molecular signaling pathways that drive or mediate
the development of HCC must be better understood.
HCC is considered a chronic inﬂammation-related
disorder, the development of which is commonly associated with hepatocyte death and compensatory proliferation1,4–10. Several classes of chemicals promote
HCC in rodents, including diethylnitrosamine (DEN),
which has been extensively studied. In the DEN-induced
HCC model, DEN stimulates DNA damage and causes
reactive oxygen species to accumulate; it also induces
hepatocyte death through the c-Jun N-terminal kinase
(JNK) pathway11–14. The dying cells release interleukin1 alpha (IL1α), which activates Kupffer cells6,15. Activated Kupffer cells produce cytokines and growth factors such as interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNFα)5,16–18, which promote expansion of
hepatocytes with DNA mutations thus enhancing HCC
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Fig. 1 Caspase-3 deﬁciency promoted DEN-induced liver cancer. a CASPASE-3, active CASPASE-3 and β-actin protein expression in the livers of
WT mice 3 days following injection with either saline (Un) or 100 mg/kg of DEN was analyzed by western blotting. Values are means ± SD, n = 3 mice
in each group. b Active CASPAPS-3 protein (red) in the livers of WT and Caspase-3 KO mice following indicated treatment was detected by IF with
nuclei counterstained with DAPI (magniﬁcation, ×400). c Photographs of livers of WT and Caspase-3 KO mice 9 months after DEN injection.
d Quantiﬁcation of liver tumor numbers (n = 6). e Quantiﬁcation of liver tumor sizes (n = 6). f Histological analysis (H&E staining) and staining of AFP
of the livers of WT and Caspase-3 KO mice 9 months after DEN injection. Bars: 20 µM. Values in (d) and (e) are means ± SDs

development5,16,17. We previously reported that deﬁciency
of PUMA (p53 upregulated modulator of apoptosis) signiﬁcantly decreased DEN-induced liver cancer by blocking acute apoptotic responses and the subsequent
compensatory proliferation19. These data provide evidence for the correlation of speciﬁc mediators of hepatocyte apoptosis and the development of HCC. Caspase-3
is a member of the cysteine-aspartic acid protease family
(caspases) and plays a central role in the execution-phase
of cellular apoptosis20. Given the strong association of
apoptosis and compensatory proliferation in HCC development, and the speciﬁc apoptotic executive function of
Caspase-3, we hypothesized that inhibition of Caspase-3
Ofﬁcial journal of the Cell Death Differentiation Association

would suppress DNA damage-induced hepatocyte death,
and thereby inhibit hepatic carcinogenesis.
Unexpectedly, we found that Caspase-3 deﬁciency signiﬁcantly promoted DEN-induced HCC development.
Intriguingly, Caspase-3 deﬁciency increased hepatocyte
death and the subsequent compensatory proliferation
induced by DEN. In addition, we discovered that Caspase3 deﬁciency increased the activation of p38 MAP kinase.
Moreover, we demonstrated that deletion of Caspase-3
increased p38 activation by IL1α and TNFα in primary
mouse hepatocytes. Furthermore, we found that inhibition of p38 abrogated enhanced hepatocyte death, the
compensatory proliferation and HCCs induced by DEN in
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Fig. 2 Caspase-3 deﬁciency increased DEN-induced hepatocyte apoptosis. Liver tissue or blood was harvested from WT and Caspase-3 KO mice
0, 3 or 10 days after a single injection of 100 mg/kg DEN. a Apoptosis in the livers of WT and Caspase-3 KO mice after treatment with vehicle or DEN
was examined by TUNEL staining. b Quantiﬁcation of TUNEL staining for (a) (n = 5). c Serum alanine aminotransferase (ALT) levels were determined
at the indicated time points after DEN treatment. Values are means ± SD, n = 4 mice in each group. d Expression of p-H2AX protein in the livers of WT
and Caspase-3 KO mice after treatment with vehicle or DEN was examined by IF. e Quantiﬁcation of p-H2AX staining for (d) (n = 5). Bars: 20 µM.
Values in (b), (c) and (e) are means ± SDs

Caspase-3-deﬁcient mice. Overall, our data suggest that
Caspase-3 inhibits chemical-induced hepatocarcinogenesis by suppressing p38 activation and hepatocyte death.

Results
DEN induced Caspase-3 cleavage in mouse livers

To determine the role of Caspase-3 in hepatocarcinogenesis, we used the DEN-induced HCC model because
Caspase-3 is cleaved and activated in response to DNA
Ofﬁcial journal of the Cell Death Differentiation Association

damage or non-genotoxic stimuli21 and DEN is known to
induce DNA damage22. We analyzed the activation of
Caspase-3 in the livers of WT mice after DEN treatment.
Cleaved Caspase-3 but not total Caspase-3 was signiﬁcantly
elevated by day 3 after treatment compared with untreated
mice (Fig. 1a). Immunostaining indicated that cleaved
Caspase-3 protein was selectively induced in hepatocytes
around the centrilobular regions 24 h after DEN treatment,
whereas the basal level was undetectable (Fig. 1b).

Shang et al. Cell Death and Disease (2018)9:558

Caspase-3 deﬁciency promoted DEN-induced liver cancer

A single injection of DEN to 15-day-old male mice
results in efﬁcient HCC induction19. To determine a
potential role for Caspase-3 in hepatocarcinogenesis, we
compared tumor incidence and size in WT and Caspase-3
knockout (Casp3 KO) littermates 9 months after DEN
treatment. All of the mice developed tumors by 9 months
of age (Fig. 1c). Interestingly, tumor incidence in Casp3
KO mice increased by about twofold compared with WT
mice (8.8 ± 2.2 vs. 3.5 ± 0.8) (Figs. 1c, d). Tumor size was
also signiﬁcantly increased in Casp3 KO mice compared
with WT mice (Figs. 1e, f). In addition, immunohistochemical (IHC) staining signals for alpha-fetoprotein
(AFP), a common HCC marker, were signiﬁcantly lower
in the livers of WT mice compared with those of Casp3
KO mice (Fig. 1f). These results indicate that Casp3
deﬁciency promotes DEN-induced hepatocarcinogenesis.
Caspase-3 deﬁciency increased DEN-induced hepatocyte
death

Caspase-3 is a critical apoptotic executor21. Promotion
of HCC development by Casp3 deﬁciency could be due to
decreased apoptosis of tumor cells. To determine whether
a deﬁciency of Casp3 affects apoptosis in DEN-induced
HCC, we performed Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining in liver
tumors from WT and Casp3 KO mice treated with DEN.
We did not ﬁnd signiﬁcant differences in apoptosis in
tumors between these two groups of mice (Fig. S1A and
S1B). We also analyzed proliferation in the DEN-treated
livers from WT and Casp3 KO mice by Ki67 staining. The
number of Ki67+ cells was comparable in Casp3-deﬁcient
and WT liver tumors (Fig. S1A and S1B). These results
show that Casp3 deﬁciency affects neither apoptosis nor
proliferation in DEN-induced HCC.
The development of DEN-induced HCC is associated
with hepatocyte death and compensatory proliferation1,4–10. DEN induces signiﬁcant hepatocyte death in
WT mice within 3 days (Figs. 2a, b), notably, in the
centrilobular regions where Caspase-3 is activated
(Figs. 1b, 2a). Interestingly, there was dramatically
enhanced hepatocyte death in Casp3 KO mice compared
with WT mice after DEN treatment (Figs. 2a, b). Hepatocyte death decreased by 10 days after DEN treatment
in both WT and Casp3 KO mice, but was greater in
Casp3 KO mice than in WT mice (Figs. 2a, b). DEN
treatment increased serum levels of the liver enzyme
alanine aminotransferase (ALT) by day 3, such increase
being similar in both Casp3 KO and WT mice (Fig. 2c).
As DEN can induce oxidative DNA damage in the liver5,
we evaluated DNA double-strand breaks in livers by pH2AX staining. No difference in DNA damage was
found between WT and Casp3 KO mice 3 or 10 days
after DEN treatment (Figs. 2d, e).
Ofﬁcial journal of the Cell Death Differentiation Association
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Caspase-6 and Caspase-7 may play similar functions as
Caspase-3 in the execution of apoptosis23. To determine if
deletion of Caspase-3 increases the activation of Caspase6 and Caspase-7 after DEN treatment in mouse livers, we
examined the expression of total and cleaved Caspase-6
and Caspase-7 in DEN-treated mouse livers. We found a
slight decrease in cleavage of Caspase-6 or Caspase-7 in
Casp3 KO mice compared with WT mice (Fig. S2), suggesting that increased DEN-induced hepatocyte apoptosis
resulting from Caspase-3 deﬁciency is not the result of
enhanced activation of Caspase-6 or Caspase-7 in DENtreated mouse livers.
Caspase-3 deﬁciency enhanced DEN-induced
compensatory proliferation

DEN-induced hepatocyte death is associated with
compensatory proliferation and HCC development19. As
expected, elevated proliferation was found in the livers of
WT mice 3 and 10 days following DEN treatment as
evidenced by Ki67 and PCNA staining (Figs. 3a–d). The
proliferation centered on the centrilobular regions where
apoptotic cells were detected (Figs. 2a, 3a). The degree of
proliferation was signiﬁcantly increased in Casp3 KO
mice compared with WT mice (Figs. 3a–d). IL-6 and its
downstream target Stat3 have been shown to play
important roles in DEN-induced compensatory proliferation5,16–18. We therefore examined the expression of
IL-6 mRNA and phosphorylation of Stat3 in WT and
Casp3 KO mouse livers. We found that IL-6 mRNA was
increased in Caspase-3 KO mouse livers compared with
WT mouse livers after DEN treatment both on day 3 and
day 10 (Fig. S3). Phosphorylation of Stat3 was also
increased in Caspase-3 KO mouse livers compared with
WT mouse livers after DEN treatment on day 3 while the
difference was diminished by day 10 (Fig. S3). These
results showed that Caspase3 deﬁciency promotes DENinduced compensatory proliferation in hepatocytes.
Caspase-3 deﬁciency enhanced p38 activation in mouse
livers

Activation of JNK, nuclear factor-κB (NF-κB) and p38
by cytokines, including TNFα and IL1α, plays a critical
role in hepatocyte death and compensatory proliferation
after DEN treatment24,25. To determine whether deletion
of Caspase-3 affects the activation of JNK, NF-κB and p38
in the liver after DEN treatment, we compared the
phosphorylation of these three proteins in the livers of
WT and Casp3 KO mice. There was no signiﬁcant difference in the phosphorylation status of JNK in Casp3 KO
mouse livers compared with WT mouse livers prior to or
after DEN treatment (Fig. 4a). NF-κB was slightly
increased by Caspase-3 deﬁciency in response to DEN
treatment by 3 days but not after 10 days (Fig. 4a).
Accordingly, phosphorylation of I-kappa-B-alpha (IκBα)
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Fig. 3 Caspase-3 deﬁciency enhanced DEN-induced compensatory proliferation. Liver tissue was harvested from WT and Caspase-3 KO mice 0,
3 and 10 days after injection of 100 mg/kg DEN. a Ki67 was measured at indicated time points by IHC. b Quantiﬁcation of Ki67 staining for
(a) (n = 5). c Proliferating cell nuclear antigen (PCNA) was measured at indicated time points by IF. d Quantiﬁcation of Ki67 staining for (c) (n = 5).
Bars: 20 µM. Values in (b) and (d) are means ± SDs

on Ser 32 and Ser 36, which results in release and nuclear
translocation of active NF-κB26, was also slightly
increased by Caspase-3 deﬁciency in response to DEN
treatment on day 3 after treatment (Fig. S4A). We also
examined levels of IκBα, Vcam1 and Cxcl10 mRNA,
which have been reported to be direct target genes of NFκB27,28. We found that the expression of Vcam1 and
Cxcl10 but not IκBα was increased by Caspase-3 deﬁciency in response to DEN treatment in mouse livers (Fig.
S4B). NF-κB has been shown to protect against DENinduced hepatocyte death and HCC5,24. Therefore, it is
unlikely that an increase in NF-κB activation led to
enhanced DEN-induced hepatocyte death, compensatory
proliferation and HCC caused by Caspase-3 deﬁciency.
Interestingly, higher p-p38 was observed in Casp3 KO
mouse livers compared with WT mouse livers with or
without DEN treatment (Fig. 4a), suggesting that deletion
of Caspase-3 increases the activation of p38 in mouse
livers. Consistently, phosphorylation of MK2, a downstream direct target of p38, was also increased in Casp3
Ofﬁcial journal of the Cell Death Differentiation Association

KO mouse livers (Fig. S5A). MMK6 and MMK3 have
been shown to phosphorylate and activate p38. We also
found that phosphorylation of MAP kinase kinases 3/6
(MKK3/6) was increased in Casp3 KO mouse livers
(Fig. S5A).
Caspase-3 deﬁciency did not affect TNFα nor IL1α
expression in mouse livers after DEN treatment

TNFα plays a critical role in hepatocyte compensatory
proliferation and the activation of JNK, NF-κB and p38
after DEN treatment24,25. It is possible that Caspase-3
deﬁciency enhances p38 activation in mouse liver by
increasing the expression of TNFα after DEN treatment.
We therefore compared mRNA and protein levels of
TNFα in the livers of WT and Casp3 KO mice. Expression of both TNFα mRNA and protein was increased
when examined 3 days following DEN treatment in WT
mice, whereas comparable expression of TNFα was
observed in Casp3 KO mice (Fig. 4b and Fig. S5A). IL1α
has been shown to phosphorylate and activate p38 in liver
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Fig. 4 Caspase-3 deﬁciency enhanced TNFα- or IL1α-induced p38 activation in mouse hepatocytes. a Expression of p-p38, p38, p-JNK, JNK,
p-NF-κB, NF-κB, CASPASE-3 and GAPDH proteins in the livers of WT and Caspase-3 KO mice 0, 3 and 10 days following injection with either saline
(Un) or 100 mg/kg of DEN was analyzed by western blotting. b mRNA expression of Tnfα and IL1α in the livers of WT and Caspase-3 KO mice 0, 3
and 10 days following injection with either saline (Un) or 100 mg/kg of DEN was analyzed by western blotting. Values are means ± SDs, n = 3 mice
in each group. c Expression of p-p38, p38, CASPASE-3 and GAPDH proteins in isolated hepatocytes from WT and Caspase-3 KO mice 1 h after
treatment with 0, 5 or 15 ng/ml TNFα was analyzed by western blotting. d Expression of p-p38, p38, CASPASE-3 and GAPDH proteins in isolated
hepatocytes from WT and Caspase-3 KO mice 1 h after treatment with 0, 20 or 100 ng/ml IL1α was analyzed by western blotting. Values in (b) are
means ± SDs

cells29. We therefore examined the expression of IL1α
and found no signiﬁcant difference in IL1α mRNA
expression (Fig. 4b). These data indicate that Caspase-3
deﬁciency increases the activation of p38 but does not do
so through enhanced expression of TNFα or IL1α in
mouse livers.
Caspase-3 deﬁciency enhanced activation of p38
by in response to TNFα or IL1α in hepatocytes

As the expression of neither TNFα nor IL1α was
affected in mouse livers by deletion of Caspase-3, we
therefore examined whether Caspase-3 deﬁciency in
hepatocytes enhances the phosphorylation of p38 in
Ofﬁcial journal of the Cell Death Differentiation Association

response to TNFα or IL1α. We isolated primary hepatocytes from WT and Casp3 KO mice and treated them
with TNFα or IL1α. There was a signiﬁcant enhancement of p38 phosphorylation in Casp3 KO hepatocytes
compared with WT hepatocytes prior to or after treatment with TNFα (Fig. 4c). Similarly, phosphorylation of
p38 was increased in Casp3 KO hepatocytes compared
with WT hepatocytes after 1 h of IL1α treatment
(Fig. 4d). Consistently, phosphorylation of MK2 and
MKK3/6 was also increased in Casp3 KO hepatocytes
compared with WT hepatocytes after 1 h of treatment
with IL1α or TNFα (Fig. S5B and C). In general, these
data demonstrate that Caspase-3 deﬁciency enhances
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the activation of p38 in hepatocytes in response to TNFα
or IL1α.
Inhibition of p38 abrogated enhanced DEN-induced
hepatocyte death, compensatory proliferation and HCC
development induced by deletion of Caspase-3

Emerging evidence indicates that activation of p38
promotes cell death. Activation of p38 by MKK6 has been
shown to induce apoptosis in Huh7 and HepG2 cells30. A
p38 MAPK inhibitor markedly suppressed cell death
induced by TNFα31. Therefore, we reasoned that Caspase3 deﬁciency increased DEN-induced hepatocyte apoptosis
through enhanced p38 activation. To test this hypothesis,
we ﬁrst examined whether the overexpression of p38
increases TNFα-induced cell death in AML12 cells, a
mouse hepatocyte cell line. We found that overexpression
of p38 did increase TNFα-induced cell death in these cells
(Fig. S6). Further, we treated WT and Casp3 KO mice
with a speciﬁc inhibitor of p38, SB202190, prior to and
after DEN treatment. We found that SB202190 decreased
the phosphorylation of p38 in both WT and Casp3 KO
mice (Fig. 5a) and inhibited DEN-induced hepatocyte
death (Figs. 5b, c). Consistently, SB202190 also decreased
DEN-induced compensatory proliferation in Casp3 KO
mice (Fig. 5d). Importantly, SB202910 inhibited DENinduced HCC development in Casp3 KO mice (Figs. 5e, f).
These data suggest that deletion of Caspase-3 enhances
DEN-induced hepatocyte death, compensatory proliferation and the development of HCC by increasing the
activation of p38.

Discussion

Treatment options for HCC are limited2. Currently, the
most effective targeted therapeutic agent for advanced
HCC, sorafenib, an inhibitor of several protein tyrosine
kinases (including vascular endothelial growth factor
receptor and platelet-deried growth factor receptor) and
Raf kinases, increases survival in patients with advanced
HCC by only 3 months3. More effective therapeutic
strategies and agents to treat HCC are clearly needed.
Therefore, it is necessary to elucidate the molecular signaling pathways that drive or mediate the development of
HCC. Hepatocyte apoptosis has been shown to play an
important role in HCC development. About 3.5% of HCC
samples from The Cancer Genome Atlas (TCGA) liver
HCC data sets show deletion of the Caspase-3 gene,
which is correlated with reduced Caspase-3 mRNA
expression (Fig. S7). A recent study indicated that low
expression of Caspase-3 is correlated with poor prognosis
in HCC patients32, suggesting that Caspase-3 might be
involved in HCC pathogenesis. However, the role of
Caspase-3 in HCC development in vivo has not been
reported. In this study, we found that deletion of Caspase3
promotes
DEN-induced
hepatocyte
death,
Ofﬁcial journal of the Cell Death Differentiation Association

Page 7 of 11

compensatory proliferation and carcinogenesis, indicating
that Caspase-3 plays an inhibitory role in hepatocarcinogenesis. Therefore, it is likely that Caspase-3 deletion or
downregulation in human HCC samples promotes HCC
development.
Caspase-3 is a central executor of apoptosis. Therefore,
it was surprising to us that Caspase-3 deletion increases
apoptosis induced by DEN in mouse livers. Caspase-6 and
Caspase-7, the other two apoptotic executors, have been
shown to compensate the functions of Caspase-3 in some
cell contexts33. However, we observed no compensatory
activation of Caspase-6 or Caspase-7 in DEN-treated WT
or Caspase-3 KO livers. Instead, we found that loss of
Caspase-3 increases the activation of p38 in response to
DEN, TNFα or IL1α in hepatocytes. It is notable that p38
hyperactivation in Casp3 KO mice is largely constitutive
(Fig. 4a), although treatment with IL1α or TNFα promotes a further increase in phosphorylation (Fig. S5B). It
is possible that Caspase-3 deletion increases p38 activation in response to the basal level of TNFα or IL1α in
mouse liver. Activation of p38 by MKK6 has been shown
to induce apoptosis in HCC cells30. p38 also mediates cell
death induced by TNFα in cancer cells31. We also found
that overexpression of p38 enhanced TNFα-induced cell
death in mouse liver cells (Fig. S6). In addition, we
demonstrated that a p38 inhibitor abrogates the enhanced
DEN-induced hepatocyte death induced by deletion of
Caspase-3. Overall, our data suggest that Casp3 KO
hepatocytes are more sensitive to TNFα, which is likely
due to p38 hyperactiation (Fig. S6). Therefore, deletion of
Caspase-3 enhances DEN-induced hepatocyte death,
compensatory proliferation and hepatocarcinogenesis by
increasing the activation of p38 (Fig. 6). To our knowledge, this is the ﬁrst report of inhibition of p38 activation
by Casp-3. It is unknown whether this mechanism is a
general one that will be found all in cell types or whether
it is in cell context speciﬁc. It will be interesting for us to
test this question in all our future studies.
Increased activation of p38 caused by the deletion of
Caspase-3 may be due to the result of multiple actions.
MKKs 3 and 6 and have been identiﬁed as common
activators of p38 in the liver34. Indeed we found that
phosphorylation of MKK6/3 is increased in Caspase-3deﬁcient hepatocytes (Fig. S4), suggesting that Caspase-3
deletion increases the activation of p38 through enhancing MKK6/3 activation in hepatocytes. Several MAP
kinase kinase kinases have been shown to trigger MKK6/
3 activation; they include apoptosis signal-regulating
kinase 1 (ASK1), dual-leucine zipper-bearing kinase 1
(DLK1), thousand-and-one amino acid (TAO) 1 and 2,
tumor progression loci 2 (TPL2), mixed lineage kinase 3
(MLK3), MEK kinase 3 (MEKK3), MEKK4, and leucine
zipper and sterile-α motif kinase 1 (ZAK1)29. Over three
hundred targets of Caspase-3 have been identiﬁed35. It is
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Fig. 5 Inhibition of p38 abrogated enhanced DEN-induced hepatocyte death, compensatory proliferation and HCC development induced
by deletion of Caspase-3. a Expression of p-p38 and GAPDH proteins in the livers of Caspase-3 KO mice 3 days following injection with either saline
(Un) or 100 mg/kg DEN plus 20 mg/kg SB202190 was analyzed by western blotting. b Apoptosis in the livers of Caspase-3 KO mice 3 days following
injection with either saline (Un) or 100 mg/kg DEN plus 20 mg/kg SB202190 was analyzed by TUNEL staining. Bars: 20 µM. c Quantiﬁcation of TUNEL
staining for (b) (n = 3). d Quantiﬁcation of Ki67 staining in the livers of Caspase-3 KO mice 3 days after injection with either saline (Un) or 100 mg/kg
DEN plus 20 mg/kg SB202190. e Photographs of livers of WT and Caspase-3 KO mice 9 months after DEN injection with or without SB202190. f
Quantiﬁcation of liver tumor numbers (n = 5) and liver tumor sizes (n = 5) for (e). Values in (c), (d) and (f) are means ± SDs

possible that the loss of Caspase-3 increases the activation of MKK6/3 and p38 through regulating its downstream targets. Given the cell context dependence and
Ofﬁcial journal of the Cell Death Differentiation Association

multiple known targets of Caspase-3, it is not our contention that the increased activation of MKK6/p38 is the
only mechanism to explain Caspase-3’s effects. Rather,
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Fig. 6 A schematic model. In the DEN-induced HCC model, DEN
induces hepatocyte death. The dying cells release IL1α, which
activates Kupffer cells. Activated Kupffer cells produce TNFα, which
induces hepatocyte death and promotes expansion of the
hepatocytes carrying DNA mutations, thus enhancing HCC
development. p38 hyperactivation promotes TNFα-mediated
hepatocyte death. Caspase-3 suppresses p38 activation in hepatocytes
thereby Caspase-3 deletion increases the activation of p38 and
enhances hepatocyte death, the subsequent compensatory
proliferation and the development of HCC, all induced by DEN.

we posit that this mechanism is a contributor to
increased hepatocyte death, compensatory proliferation
and hepatic carcinogenesis caused by the loss of Caspase3, and can account for some, if not all, of the functional
changes observed.
In conclusion, our study shows that deﬁciency of
Caspase-3 promotes chemical-induced hepatocyte compensatory proliferation and hepatocarcinogenesis. Recent
studies suggest that speciﬁc inhibition of Casapse-3 in
concert with chemotherapy may be a novel approach for
the treatment of cancers because of the role of cell death
in promoting tissue regeneration in mammalian cells36,37.
Our data suggest that the role of Caspase-3 in cancer
development is complex and the inhibition of Caspase-3
might not be suitable for the treatment of HCC patients.

Materials and methods
Mice and treatments

All animals received humane care according to the “Guide
for the Care and Use of Laboratory Animals” (http://oacu.
od.nih.gov/ac_cbt/guide3.htm). The procedures for all animal experiments were approved by the Institutional Animal
Care and Use Committee of Loyola University Chicago.
Casp3+/+ and Casp3−/− littermate mice in a C57BL/6
background were generated from heterozygote intercrosses.
Genotyping was performed as described in the JAX Lab
Ofﬁcial journal of the Cell Death Differentiation Association

website (https://www.jax.org/strain/006233). The mice were
housed in micro-isolator cages in a room illuminated from
07:00 a.m. to 07:00 p.m. (12:12-h light–dark cycle), and
allowed access to water and chow ad libitum.
For the DEN-induced HCC model, DEN (15 mg/kg) was
injected intraperitoneally (i.p.) into 15-day-old mice. Mice
were sacriﬁced after 9 months on the standard diet. Surface tumor nodules in each liver lobe were counted and
measured with a caliper. For short-term studies of DENinduced liver injury, 8- to 12-week-old mice were injected
with DEN (100 mg/kg body weight) i.p. and sacriﬁced
after 3 or 10 days.
For p38 inhibitor treatments, SB202190 (LC Laboratories, Cat # S-1700) was diluted in 6% captisol (CyDex,
Inc., Lenexa, KS). One day prior to DEN treatment, six
2-week-old or 8- to 12-week-old WT and six 2-week-old
or 8- to 12-week-old Casp3−/− mice were administered
vehicle solution (6% captisol) or 20 mg/kg SB202190 by i.
p. daily for 3 days and livers were collected 9 months, 3 or
10 days after DEN treatment.
Isolation and culture of primary mouse hepatocytes

Hepatocytes from Casp3+/+ and Casp3−/− mice were
isolated by the non-recirculating two-step perfusion
method as previously described38. The hepatocytes were
then cultured in Williams’ medium E supplemented with
Hepatocyte Maintenance Supplement Pack (Life Technologies, Grand Island, NY) overnight. Cells were treated
with 5 ng/ml and 20 ng/ml IL1α or 5 ng/ml and 15 ng/ml
TNFα for 1 h; proteins were subsequently collected for
western blot analysis.
Culture and treatment of AML12 cells

AML12 cells were purchased from ATCC and cultured
as per the manufacturer's recommendations. Cells were
transfected with pCNA3 or pCNA3-p38α (Addgene,
#20352) plasmids followed by treatment with either saline
(vehicle) or 20 ng/ml TNFα for 48 h. Viability of the cells
was analyzed by Alamar Blue Assay.
ALT measurement

Venous blood of mice was collected from the tail vein 0,
24, and 72 h after DEN treatment. Blood was kept at 4 °C
for overnight and centrifuged at 200 × g for 20 min to
isolate serum. ALT was measured using the Inﬁnity™ ALT
kit (Thermo Scientiﬁc, Middletown, VA) and is reported
as mean ± SD. Brieﬂy, 10 μl of serum was added to 100 μl
ALT reagent and measured at 37 °C at 340 nm. Each
sample was measured in triplicate and three mice were
used in each group.
Western blotting

Western blotting was performed as previously described38. Primary antibodies, against Caspase-3 (9662), active
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Caspase-3 (9661), Caspase-6 (9762), active Caspase-6
(9761), Caspase-7 (9492), active Caspase-7 (8438), JNK
(9252), p-JNK (9255), NF-κB (8242), p-NF-κB (3033), p38
(8690), p-p38 (4631), p-MK2 (3007), MKK3 (8535), MKK6
(8550), p-MKK3/6 (12280), were purchased from Cell
Signaling Technologies (Danvers, MA).
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TUNEL staining

TUNEL staining was performed as previously described38,39. The apoptotic index was scored in at least ﬁve
ﬁelds at ×400 magniﬁcation/mouse and reported as mean
± SD. Three mice were used for each group.
IHC staining

IHC was performed as previously described38,40. Cells
with positive staining were scored in at least ﬁve ﬁelds at
×400 or ×200 magniﬁcation and reported as mean ± SD.
Three mice were used per group.
Total RNA extraction and real-time reverse transcriptase
polymerase chain reaction

Approximately 100 mg of fresh tissue was minced and
put into 600 μl lysis buffer (Promega). Total RNA was
isolated, and complementary DNA was then generated for
real-time PCR analysis as described40. Real-time PCR was
performed on a Mini Opticon Real-time PCR system (BioRad) with SYBR Green (Invitrogen) and speciﬁc primers19. Melting curves and agarose gel electrophoresis of
the PCR products were used to verify the speciﬁcity of
PCR ampliﬁcation.
Statistical analysis

Statistical analysis was performed using GraphPad
Prism V software. Data are presented as means ± standard
deviations (SD). Statistical signiﬁcance was calculated
using the Student’s t-test. P < 0.05 was considered to be
signiﬁcant. The means ± SDs are shown in ﬁgures where
applicable.
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